Keywords: Valeant, PharmaSwiss, Generics, OTCs, M&A
Valeant Pharmaceuticals to buy generic/OTC drugmaker PharmaSwiss for $480 million
Article | 02 February 2011
Canada-based Valeant Pharmaceuticals International (NYSE: VRX; TSX: VRX) has signed a binding agreement to acquire PharmaSwiss, a privately-owned branded generics ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
